April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Two Year Results of Photodynamic Therapy for Polypoidal Choroidal Vasculopathy
Author Affiliations & Notes
  • G. Miura
    Ophthalmology, Chiba University, Chiba, Japan
  • M. Kitahashi
    Ophthalmology, Chiba University, Chiba, Japan
  • M. Kubota
    Ophthalmology, Chiba University, Chiba, Japan
  • Y. Mitamura
    Ophthalmology, Chiba University, Chiba, Japan
  • S. Yamamoto
    Ophthalmology, Chiba University, Chiba, Japan
  • Footnotes
    Commercial Relationships  G. Miura, None; M. Kitahashi, None; M. Kubota, None; Y. Mitamura, None; S. Yamamoto, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 242. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. Miura, M. Kitahashi, M. Kubota, Y. Mitamura, S. Yamamoto; Two Year Results of Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. Invest. Ophthalmol. Vis. Sci. 2009;50(13):242.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To investigate the 2 year outcome of photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV).

Methods: : This retrospective study involved 56 eyes of 55 PCV patients followed for at least 24 months after PDT. The best-corrected visual acuity (BCVA), fluorescein and indocyanine green angiographic results, and foveal thicknesses were investigated before and after PDT.

Results: : The mean number of PDT treatments was 1.6±0.7. Twenty-four eyes (42.9%) required retreatment by PDT because of recurrences. The mean period until the first recurrence was 11.4±7.4 months. The mean BCVA was 0.73±0.20 logMAR units before the initial PDT, 0.65±0.45 logMAR units at 12 months, and 0.75±0.53 logMAR units at 24 months. The mean fovea thickness was 459.4±210.2 µm before the initial PDT, 235.3±177.6 µm at 12 months, and 238.5±189.6 µm at 24 months postoperatively. The BCVA in 41 eyes (73%) did not change (within ±0.2 logMAR units) or improve (>0.2 logMAR units) before and 24 months after PDT. However, the BCVA in 11 eyes (45%) of the 24 eyes that had had a recurrence worsened to >0.2 logMAR units during the 24 months follow-up period.

Conclusions: : PDT is an effective treatment to preserve VA against PCV. However, approximately 43% of all cases had a recurrence within 24 months, and 11% had the first recurrence 18 months after their first PDT treatment. Once PCV recurred, the VA prognosis worsened significantly. Long-term careful observation is needed for PCV after PDT treatment.

Keywords: age-related macular degeneration 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.